Nicholas A. Gray

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Barriers to Timely Arteriovenous Fistula Creation: A Study of Providers and Patients

Pamela Lopez‐Vargas, Jonathan C. Craig, Martin Gallagher et al. · American Journal of Kidney Diseases · 2011 · 93 citations

Primary Care, Patient Safety, Vascular Surgery +4

A Trial of Extending Hemodialysis Hours and Quality of Life

Meg Jardine, Li Zuo, Nicholas A. Gray et al. · Journal of the American Society of Nephrology · 2017 · 78 citations

The impact of automated eGFR reporting and education on nephrology service referrals

Euan Noble, David W. Johnson, Nicholas A. Gray et al. · Nephrology Dialysis Transplantation · 2008 · 76 citations · Full text